Upneeq® Wins 2024 Shape Skin Award, "Best for Lift", in the Professional Treatment Category
RVL Pharmaceuticals announced today that its prescription eye drop, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as a 2024 Shape Skin Award winner by Shape Magazine, named "Best for Lift" in the professional category. This is the third Shape award for Upneeq. The product was also named as a "Best Professional Grade'' treatment by editors in 2022 and received a 2023 Shape Beauty Award for "Best In-Office" treatments. Upneeq is FDA approved for the treatment of acquired ptosis (droopy eyelids) in adults.
For the 2024 Shape Skin Awards, editors tested over 225 expert-backed face, body, and hair products, facial devices, and aesthetic medical treatments, consulting with board-certified industry experts and researching over a dozen published skincare studies to inform the winning selections. Products were evaluated for their effectiveness, innovation, and performance. 37 winners were ultimately chosen, and judges awarded Upneeq for its subtle but noticeable lift for droopy eyelids.
"We are incredibly grateful to Shape Magazine for recognizing Upneeq as a top player in the beauty industry for the third year in a row and are honored to be named as the ?Best for Lift'," said Jennifer Hanlon, Head of Digital Marketing and Consumer Technology at RVL Pharmaceuticals. "Shape is an empowering and trusted voice in health and beauty with a committed community to quality self-care. Being a part of this awards program, supported by editors and industry experts alike, is a testament to Upneeq's performance and impact."
Upneeq is a one-of-a-kind, daily eyedrop for adult patients with acquired ptosis that lifts the eyelid to create a more open eye area. Upneeq is available at eye care, dermatology, plastic surgery and medical aesthetic practices nationwide, as well as SkinSolutions.MD via telehealth appointment. In clinical trials, Upneeq demonstrated statistically significant improvements compared to placebo in both superior visual field and eyelid lift, as measured in two pivotal double-masked efficacy studies. The most common adverse reactions with Upneeq (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache. For more information, visit www.Upneeq.com
IMPORTANT SAFETY INFORMATION
What is Upneeq®? Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis (low-lying lids) in adults.
What are the most common side effects of Upneeq®?
- The most common adverse reactions with Upneeq® (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.
What warnings and precautions are associated with Upneeq®?
- Upneeq® is a type of medication that may affect your blood pressure. If you have heart disease, uncontrolled high or low blood pressure, or feel faint at rest or when quickly standing up, you should call your doctor if your symptoms get worse.
- Upneeq® may increase the risk of eye pressure due to fluid buildup (angle-closure glaucoma) in patients with untreated narrow-angle glaucoma. Call your doctor immediately if you feel increased pressure in your eye after using Upneeq®.
- Do not let the tip of the Upneeq® vial touch your eye or any other surface. This can help prevent eye injury or contamination. Each Upneeq® vial is for one-time use and should be discarded after being used.
- Low-lying lids may also be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions.
- Patients with reduced blood flow to the brain or heart, or patients who experience eye or mouth dryness due to an immune system disorder (Sjögren's syndrome), should use care when taking Upneeq®. Call your doctor immediately if you feel your symptoms may be getting worse.
What should my doctor know about before prescribing me Upneeq®?
- Your doctor should review your full medical history before prescribing Upneeq®.
- Upneeq® belongs to a class of medication (alpha-adrenergic agonists) that may affect your blood pressure. Use Upneeq® carefully if you currently take an alpha-adrenergic agonist medication to treat heart disease or an enlarged prostate. Patients taking beta-blockers, or other medications to treat hypertension or an abnormal heartbeat, should also be careful when using Upneeq®.
- Patients who use a certain class of antidepressant medication (monoamine oxidase inhibitors) should also be careful when using Upneeq®, as it may affect the way your body absorbs the medication.
This is a summary of the most important safety information for Upneeq®. For more in-depth safety information, please review the full Prescribing Information for Upneeq®.
To report a side effect, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report side effects to the FDA by calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.
About RVL Pharmaceuticals, Inc.
RVL Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the commercialization of Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelids, in adults. Upneeq is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.
About Shape
Shape is an award-winning digital fitness, wellness, and beauty destination that offers inclusive, trusted, and empowering expert-led guidance and advice for anyone at any point in their wellness journey. Their library of more than 11,000 stories reaches more than 7 million readers monthly who want to prioritize their health, have fun, and lead an active lifestyle while also cutting through the noise of quick fixes and unvetted fads.
News published on and distributed by:
